Genus PLC
LSE:GNS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 630
2 354
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GNS stock under the Base Case scenario is 2 117.74 GBX. Compared to the current market price of 1 810 GBX, Genus PLC is Undervalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Genus PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GNS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Genus PLC
Balance Sheet Decomposition
Genus PLC
Current Assets | 271.1m |
Cash & Short-Term Investments | 42.5m |
Receivables | 137.3m |
Other Current Assets | 91.3m |
Non-Current Assets | 757.8m |
Long-Term Investments | 61.6m |
PP&E | 479.4m |
Intangibles | 175.7m |
Other Non-Current Assets | 41.1m |
Current Liabilities | 150.6m |
Accounts Payable | 123.2m |
Other Current Liabilities | 27.4m |
Non-Current Liabilities | 330.1m |
Long-Term Debt | 272.3m |
Other Non-Current Liabilities | 57.8m |
Earnings Waterfall
Genus PLC
Revenue
|
668.8m
GBP
|
Operating Expenses
|
-614.6m
GBP
|
Operating Income
|
54.2m
GBP
|
Other Expenses
|
-46.3m
GBP
|
Net Income
|
7.9m
GBP
|
Free Cash Flow Analysis
Genus PLC
GBP | |
Free Cash Flow | GBP |
The company delivered solid yearly results, with actual currency-adjusted operating profit rising by 10%. While adjusted profit before tax remained flat at ÂŁ71.5 million, R&D investments grew, led by a 66% increase in gene editing costs as regulatory approval for a disease-resistant pig looms near. This increased spend dampened operating profit margins to 12.4%. Looking ahead to FY 2024, the company anticipates meeting medium-term profit growth targets in constant currency, despite expecting only modest profit before tax growth due to currency and interest rate challenges. An exciting milestone awaiting investors is the potential FDA approval of their PRRSv resistant pig.
What is Earnings Call?
GNS Profitability Score
Profitability Due Diligence
Genus PLC's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Genus PLC's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
GNS Solvency Score
Solvency Due Diligence
Genus PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Genus PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GNS Price Targets Summary
Genus PLC
According to Wall Street analysts, the average 1-year price target for GNS is 2 600.71 GBX with a low forecast of 2 070.5 GBX and a high forecast of 3 255 GBX.
Dividends
Current shareholder yield for GNS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Genus Plc engages in the provision of genetic livestock services to produce meat and milk. The company is headquartered in Basingstoke, Hampshire and currently employs 3,096 full-time employees. The company went IPO on 2000-07-06. The firm provides farmers with genetics that enable them to produce animal protein for breeding pigs and cattle, in the form of meat and milk. The Company’s operating segments includes Genus PIC, Genus ABS and Research and Development. The Genus PIC segment is engaged in porcine sales business. The Genus ABS segment is engaged in bovine sales business. The firm's development activities include developing and maintaining its porcine genetic nucleus herd and bovine pre-stud herds. The firm operates approximately around 25 countries on six continents, with research laboratories located in Madison, Wisconsin, United States.
Contact
IPO
Employees
Officers
The intrinsic value of one GNS stock under the Base Case scenario is 2 117.74 GBX.
Compared to the current market price of 1 810 GBX, Genus PLC is Undervalued by 15%.